AICLRs 31.0+9.1%BERGRs 36.5-14.4%PRLRs 147.7+44.2%AGLRs 16.9+69.1%KAPCORs 51.5+57.5%SITCRs 52.5-4.6%NMLRs 374.1+210.3%NETSOLRs 5,771.3+29.7%BOPRs 138.7-11.7%PSORs 443.1+105.3%NPLRs 18.7+89.3%FMLRs 288.6+94.9%MARIRs 23.5-11.0%THALLRs 140.6+110.3%NRLRs 61.3-22.3%HBLRs 451.9-6.7%SYSRs 1,566.1+36.2%GATMRs 79.9+33.4%GHGLRs 1,075.6+1.5%FCEPLRs 85.0+61.6%PNSCRs 566.1-42.5%AVNRs 463.8+57.3%FFLRs 135.5+33.3%AGTLRs 159.5-34.9%FEROZRs 274.0+45.3%SRVIRs 38.0+63.0%ILPRs 26.7+20.5%KELRs 71.8+64.8%MLCFRs 1.8-5.9%HTLRs 157.8+46.7%PIOCRs 54.6+58.7%IGIHLRs 98.5-4.8%EFERTRs 76.5+20.3%FFCRs 14.2-30.0%GHNIRs 476.1+34.4%PTCRs 14,713.1+1.5%TPLPRs 2,078.1+10.1%UBLRs 355.3-25.8%ISLRs 171.0+2.7%APLRs 38.3+9.0%ABOTRs 4.4-26.4%PKGSRs 61.2+35.3%FABLRs 263.0-1.9%ATLHRs 10.6-5.5%OGDCRs 71.0+43.4%MTLRs 106.9-27.7%NCLRs 5.7+56.9%UNITYRs 758.2+41.8%LUCKRs 67.7+22.9%KTMLRs 158.5+51.2%SNBLRs 172.8+16.1%BWCLRs 196.5+40.1%CHCCRs 25.0-4.0%ASTLRs 9.1+14.5%ITTEFAQRs 12.3-9.9%AGPRs 30.8-42.3%HINOONRs 61.3-35.9%ENGRORs 68.6+46.4%ATRLRs 26.4+81.9%SHELRs 187.1-5.4%JDWSRs 2.1+20.6%EFUGRs 50.9+44.1%KOHCRs 79.1+42.0%BNWMRs 54.3+62.8%GLAXORs 56.9+14.0%CNERGYRs 49.2-1.8%JSBLRs 377.8-24.1%SEARLRs 21.7-21.2%MCBRs 81.8-4.4%BAFLRs 110.1+14.1%TGLRs 236.2-8.1%NCPLRs 27.7+19.9%AIRLINKRs 81.3+23.7%PAELRs 27.5+77.4%PAKTRs 1.7+3.6%INDURs 74.3-34.6%EPCLRs 17.8-50.1%TRGRs 100.9+18.5%SNGPRs 3.6-7.2%MEBLRs 95.1+11.0%PPLRs 12.0+27.2%POLRs 149.8+69.1%BAHLRs 123.3-17.6%GWLCRs 18.0+9.8%ACPLRs 41.8+19.4%FCCLRs 146.4+6.4%HCARRs 752.9-10.6%NBPRs 173.6-16.9%FATIMARs 237.9+68.5%SSGCRs 12.9+40.7%AKBLRs 268.1-10.1%LOTCHEMRs 65.9-7.3%NATFRs 5.0-57.8%MUGHALRs 76.8-47.2%PSMCRs 514.2-32.5%ICIRs 268.1+5.8%HUBCRs 48.3+16.8%NESTLERs 4.6-50.6%ARPLRs 89.9-12.9%DGKCRs 681.9+39.9%PSELRs 113.5-0.4%AICLRs 31.0+9.1%BERGRs 36.5-14.4%PRLRs 147.7+44.2%AGLRs 16.9+69.1%KAPCORs 51.5+57.5%SITCRs 52.5-4.6%NMLRs 374.1+210.3%NETSOLRs 5,771.3+29.7%BOPRs 138.7-11.7%PSORs 443.1+105.3%NPLRs 18.7+89.3%FMLRs 288.6+94.9%MARIRs 23.5-11.0%THALLRs 140.6+110.3%NRLRs 61.3-22.3%HBLRs 451.9-6.7%SYSRs 1,566.1+36.2%GATMRs 79.9+33.4%GHGLRs 1,075.6+1.5%FCEPLRs 85.0+61.6%PNSCRs 566.1-42.5%AVNRs 463.8+57.3%FFLRs 135.5+33.3%AGTLRs 159.5-34.9%FEROZRs 274.0+45.3%SRVIRs 38.0+63.0%ILPRs 26.7+20.5%KELRs 71.8+64.8%MLCFRs 1.8-5.9%HTLRs 157.8+46.7%PIOCRs 54.6+58.7%IGIHLRs 98.5-4.8%EFERTRs 76.5+20.3%FFCRs 14.2-30.0%GHNIRs 476.1+34.4%PTCRs 14,713.1+1.5%TPLPRs 2,078.1+10.1%UBLRs 355.3-25.8%ISLRs 171.0+2.7%APLRs 38.3+9.0%ABOTRs 4.4-26.4%PKGSRs 61.2+35.3%FABLRs 263.0-1.9%ATLHRs 10.6-5.5%OGDCRs 71.0+43.4%MTLRs 106.9-27.7%NCLRs 5.7+56.9%UNITYRs 758.2+41.8%LUCKRs 67.7+22.9%KTMLRs 158.5+51.2%SNBLRs 172.8+16.1%BWCLRs 196.5+40.1%CHCCRs 25.0-4.0%ASTLRs 9.1+14.5%ITTEFAQRs 12.3-9.9%AGPRs 30.8-42.3%HINOONRs 61.3-35.9%ENGRORs 68.6+46.4%ATRLRs 26.4+81.9%SHELRs 187.1-5.4%JDWSRs 2.1+20.6%EFUGRs 50.9+44.1%KOHCRs 79.1+42.0%BNWMRs 54.3+62.8%GLAXORs 56.9+14.0%CNERGYRs 49.2-1.8%JSBLRs 377.8-24.1%SEARLRs 21.7-21.2%MCBRs 81.8-4.4%BAFLRs 110.1+14.1%TGLRs 236.2-8.1%NCPLRs 27.7+19.9%AIRLINKRs 81.3+23.7%PAELRs 27.5+77.4%PAKTRs 1.7+3.6%INDURs 74.3-34.6%EPCLRs 17.8-50.1%TRGRs 100.9+18.5%SNGPRs 3.6-7.2%MEBLRs 95.1+11.0%PPLRs 12.0+27.2%POLRs 149.8+69.1%BAHLRs 123.3-17.6%GWLCRs 18.0+9.8%ACPLRs 41.8+19.4%FCCLRs 146.4+6.4%HCARRs 752.9-10.6%NBPRs 173.6-16.9%FATIMARs 237.9+68.5%SSGCRs 12.9+40.7%AKBLRs 268.1-10.1%LOTCHEMRs 65.9-7.3%NATFRs 5.0-57.8%MUGHALRs 76.8-47.2%PSMCRs 514.2-32.5%ICIRs 268.1+5.8%HUBCRs 48.3+16.8%NESTLERs 4.6-50.6%ARPLRs 89.9-12.9%DGKCRs 681.9+39.9%PSELRs 113.5-0.4%

Compare Watch

GLAXO

HOLD

GlaxoSmithKline Pakistan

Pharmaceuticals · 0.36% of the KSE-100

Price

Rs 56.85

Market cap

Rs 17.4bn

12-month return

+14.0%

Rank

65 of 101

48composite

Rule-based56

ML ranker33

Conviction54

Why the engine ranks it here

GlaxoSmithKline Pakistan (GLAXO) screens as fairly valued against the rest of the KSE-100, ranking 65 of 101 on a composite score of 48/100.

GlaxoSmithKline Pakistan sits in the Pharmaceuticals sector and scores best on growth (63/100), weakest on price trend (52/100). At PKR 56.85 the shares trade on a P/E of 0.5x, 0.13x book, a 60.0% dividend yield. The Piotroski F-Score is 8 of 9 (very strong) and the Altman Z''-Score is 7.97 (financially sound).

What it does well

GLAXO has compounded revenue at 18.7% a year over three years.

Growth

GLAXO earns 31.5% on shareholders' money, well ahead of its Pharmaceuticals peers.

Profitability & earnings quality

GLAXO is unusually steady at 23.7% annualised volatility.

Price trend

What holds it back

GLAXO books 3.3% of assets as accruals, so profit is running ahead of cash.

Profitability & earnings quality

GLAXO converts profit to cash at only 0.73x.

Profitability & earnings quality

GLAXO carries heavy debt at 0.50x of equity.

Balance-sheet strength

What would change this view

→ the price reclaiming its 200-day average on rising volume

Five-pillar breakdown

Each pillar scores the company against sector peers, where 50 is the sector average.

Profitability & earnings quality30% weight58

Valuation25% weight54

Balance-sheet strength20% weight53

Growth15% weight63

Price trend10% weight52

The classic screens

Piotroski tests nine accounting facts about improvement; Altman scores the distance from financial distress.

Piotroski F-Score

8 / 9

very strong · 8 of 9 tests passed

Altman Z''-Score

7.97

safe zone · safe above 5.85

Profitable on assets

ROA 12.3%

Cash generative

CFO PKR 27,638m

Returns improving

ROA 12.3% vs 9.2% a year ago

Earnings backed by cash

CFO PKR 27,638m vs profit PKR 37,682m

Deleveraging

debt/assets 0.20 vs 0.21

Liquidity improving

current ratio 2.02 vs 1.97

Margin expanding

gross margin 35.0% vs 32.1%

Assets working harder

asset turnover 1.74x vs 1.73x

No shareholder dilution

307m shares vs 307m

Altman components

Working capital / assets0.253

Retained earnings / assets0.369

Operating profit / assets0.176

Equity / liabilities0.644

Sales / assets1.601

Price history

Weekly closes. Beta 0.60 against the index, annualised volatility 24%, RSI 53.

+100.5% over this window

Reported accounts

The last twelve quarters as filed, in PKR millions. The publication date is what the engine uses to decide when a figure became knowable.

Quarter	Revenue	Gross profit	Operating	Net income	EPS	Filed
2025 Q4	Rs 147.9bn	Rs 61.5bn	Rs 20.3bn	Rs 13.4bn	43.53	2026-04-30
2025 Q3	Rs 143.8bn	Rs 56.6bn	Rs 18.4bn	Rs 12.0bn	39.19	2025-11-14
2025 Q2	Rs 142.6bn	Rs 39.8bn	Rs 11.5bn	Rs 7.3bn	23.64	2025-08-14
2025 Q1	Rs 130.8bn	Rs 52.5bn	Rs 17.1bn	Rs 11.2bn	36.38	2025-05-15
2024 Q4	Rs 117.8bn	Rs 38.5bn	Rs 11.8bn	Rs 7.3bn	23.65	2025-04-30
2024 Q3	Rs 116.3bn	Rs 39.3bn	Rs 12.2bn	Rs 7.1bn	23.16	2024-11-14
2024 Q2	Rs 118.4bn	Rs 47.4bn	Rs 15.5bn	Rs 8.9bn	29.18	2024-08-14
2024 Q1	Rs 117.5bn	Rs 27.2bn	Rs 7.2bn	Rs 3.2bn	10.43	2024-05-15
2023 Q4	Rs 107.9bn	Rs 33.9bn	Rs 10.3bn	Rs 5.2bn	17.11	2024-04-29
2023 Q3	Rs 106.0bn	Rs 24.6bn	Rs 6.5bn	Rs 2.6bn	8.47	2023-11-14
2023 Q2	Rs 112.0bn	Rs 36.8bn	Rs 11.3bn	Rs 6.1bn	19.93	2023-08-14
2023 Q1	Rs 106.4bn	Rs 18.8bn	Rs 4.2bn	Rs 1.5bn	5.05	2023-05-15

Ranked against Pharmaceuticals

Every peer in the same sector, ordered by composite score. These are the companies whose ratios set this one's z-scores.

FEROZFerozsons Laboratories2.1x61

ABOTAbbott Laboratories Pakistan0.4x55

AGPAGP Limited0.4x50

HINOONHighnoon Laboratories0.5x50

GLAXOGlaxoSmithKline Pakistan0.5x48

SEARLThe Searle Company0.5x46

Scored as of 31 December 2025. Generated by an automated screen for research and educational use. Not investment advice, and not a substitute for a SECP-licensed adviser.